{"id":16651,"date":"2014-03-06T09:15:46","date_gmt":"2014-03-06T14:15:46","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=16651"},"modified":"2014-03-06T07:36:30","modified_gmt":"2014-03-06T12:36:30","slug":"insys-therapeutics-inc-nasdaqinsy-returns-to-profitability-with-q4-earnings","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/insys-therapeutics-inc-nasdaqinsy-returns-to-profitability-with-q4-earnings-16651","title":{"rendered":"Insys Therapeutics Inc. (NASDAQ:INSY) Returns to Profitability with Q4 Earnings"},"content":{"rendered":"<p style=\"text-align: justify;\">Boston, MA 03\/06\/2014 (wallstreetpr) &#8211; <b>Insys Therapeutics Inc. (NASDAQ:INSY)<\/b> was one of the top gainers after reporting impressive earnings for its fourth quarter that beat analysts\u2019 estimates. The strong results reported for the quarter and full year were heavily impacted by strong growth in the Subsys prescriptions that are used to alleviate pain in patients with cancer.<\/p>\n<p style=\"text-align: justify;\"><b>Fourth Quarter Financial<\/b><\/p>\n<p style=\"text-align: justify;\">Total revenue for the fourth quarter was one of the top gainers having moved up by as much as $35 million to highs $40.2 million in the fourth quarter as compared to the same quarter a year ago. Fourth quarter revenue was also up by $11 million as compared to the third quarter of the same financial year which stood at $29 million. Total revenue for the full year ending December 31, 2013 clocked in at $99.3 million an increase from $15. Million reported as of December 31, 2012<\/p>\n<p style=\"text-align: justify;\">Gross margin for the fourth quarter stood at 87%, an improvement when compared to the 60% margin reported for the same quarter a year ago. The increase in the gross margin was mainly as a result of a shift in sales mix that mainly focused on Subsys.<\/p>\n<p style=\"text-align: justify;\">Insys Therapeutics Inc. (NASDAQ:INSY) sales and marketing expenses clocked in at $10.5million for the quarter up from $3.2 million reported in the same quarter a year ago. Gross margin for full year ending December 2013 came in at 87% compared to 2012\u2019s 51%.<\/p>\n<p style=\"text-align: justify;\">Research and development expenses came in at $3.2 million compared to $0.7 million registered in the same quarter a year ago while General and administrative expenses came in at $7.0 million against $2.6 million reported in the same quarter in F2012.<\/p>\n<p style=\"text-align: justify;\">Insys Therapeutics Inc. (NASDAQ:INSY) net income for the quarter came in at $24.1 million compared to a net loss of $7.1 million reported in the same quarter a year ago<\/p>\n<p style=\"text-align: justify;\">Insys Therapeutics Inc. (NASDAQ:INSY) went down by 8.94% in Wednesday trading session closing the day at a low of $75.92<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston, MA 03\/06\/2014 (wallstreetpr) &#8211; Insys Therapeutics Inc. (NASDAQ:INSY) was one of the top gainers after reporting impressive earnings for its fourth quarter that beat [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":16669,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[2236,264],"tags":[4912,4913],"stock_ticker":[],"class_list":["post-16651","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business","category-health","tag-insys-therapeutics-inc-nasdaqinsy","tag-nasdaqinsy","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Insys Therapeutics Inc. (NASDAQ:INSY) Returns to Profitability with Q4 Earnings - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/insys-therapeutics-inc-nasdaqinsy-returns-to-profitability-with-q4-earnings-16651\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Insys Therapeutics Inc. (NASDAQ:INSY) Returns to Profitability with Q4 Earnings - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Boston, MA 03\/06\/2014 (wallstreetpr) &#8211; Insys Therapeutics Inc. (NASDAQ:INSY) was one of the top gainers after reporting impressive earnings for its fourth quarter that beat [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/insys-therapeutics-inc-nasdaqinsy-returns-to-profitability-with-q4-earnings-16651\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2014-03-06T14:15:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Insys-Therapeutics-Inc..jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"355\" \/>\n\t<meta property=\"og:image:height\" content=\"142\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Donna Fago\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Donna Fago\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/insys-therapeutics-inc-nasdaqinsy-returns-to-profitability-with-q4-earnings-16651#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/insys-therapeutics-inc-nasdaqinsy-returns-to-profitability-with-q4-earnings-16651\"},\"author\":{\"name\":\"Donna Fago\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84\"},\"headline\":\"Insys Therapeutics Inc. (NASDAQ:INSY) Returns to Profitability with Q4 Earnings\",\"datePublished\":\"2014-03-06T14:15:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/insys-therapeutics-inc-nasdaqinsy-returns-to-profitability-with-q4-earnings-16651\"},\"wordCount\":320,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/insys-therapeutics-inc-nasdaqinsy-returns-to-profitability-with-q4-earnings-16651#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Insys-Therapeutics-Inc..jpg\",\"keywords\":[\"Insys Therapeutics Inc. (NASDAQ:INSY)\",\"NASDAQ:INSY\"],\"articleSection\":[\"Business\",\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/insys-therapeutics-inc-nasdaqinsy-returns-to-profitability-with-q4-earnings-16651#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/insys-therapeutics-inc-nasdaqinsy-returns-to-profitability-with-q4-earnings-16651\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/insys-therapeutics-inc-nasdaqinsy-returns-to-profitability-with-q4-earnings-16651\",\"name\":\"Insys Therapeutics Inc. (NASDAQ:INSY) Returns to Profitability with Q4 Earnings - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/insys-therapeutics-inc-nasdaqinsy-returns-to-profitability-with-q4-earnings-16651#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/insys-therapeutics-inc-nasdaqinsy-returns-to-profitability-with-q4-earnings-16651#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Insys-Therapeutics-Inc..jpg\",\"datePublished\":\"2014-03-06T14:15:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/insys-therapeutics-inc-nasdaqinsy-returns-to-profitability-with-q4-earnings-16651#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/insys-therapeutics-inc-nasdaqinsy-returns-to-profitability-with-q4-earnings-16651\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/insys-therapeutics-inc-nasdaqinsy-returns-to-profitability-with-q4-earnings-16651#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Insys-Therapeutics-Inc..jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Insys-Therapeutics-Inc..jpg\",\"width\":355,\"height\":142},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/insys-therapeutics-inc-nasdaqinsy-returns-to-profitability-with-q4-earnings-16651#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Insys Therapeutics Inc. (NASDAQ:INSY) Returns to Profitability with Q4 Earnings\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84\",\"name\":\"Donna Fago\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg\",\"caption\":\"Donna Fago\"},\"description\":\"I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.\",\"sameAs\":[\"http:\/\/www.WallStreetPR.com\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/darcie-fago\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Insys Therapeutics Inc. (NASDAQ:INSY) Returns to Profitability with Q4 Earnings - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/insys-therapeutics-inc-nasdaqinsy-returns-to-profitability-with-q4-earnings-16651","og_locale":"en_US","og_type":"article","og_title":"Insys Therapeutics Inc. (NASDAQ:INSY) Returns to Profitability with Q4 Earnings - Wall Street PR","og_description":"Boston, MA 03\/06\/2014 (wallstreetpr) &#8211; Insys Therapeutics Inc. (NASDAQ:INSY) was one of the top gainers after reporting impressive earnings for its fourth quarter that beat [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/insys-therapeutics-inc-nasdaqinsy-returns-to-profitability-with-q4-earnings-16651","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2014-03-06T14:15:46+00:00","og_image":[{"width":355,"height":142,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Insys-Therapeutics-Inc..jpg","type":"image\/jpeg"}],"author":"Donna Fago","twitter_misc":{"Written by":"Donna Fago","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/insys-therapeutics-inc-nasdaqinsy-returns-to-profitability-with-q4-earnings-16651#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/insys-therapeutics-inc-nasdaqinsy-returns-to-profitability-with-q4-earnings-16651"},"author":{"name":"Donna Fago","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84"},"headline":"Insys Therapeutics Inc. (NASDAQ:INSY) Returns to Profitability with Q4 Earnings","datePublished":"2014-03-06T14:15:46+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/insys-therapeutics-inc-nasdaqinsy-returns-to-profitability-with-q4-earnings-16651"},"wordCount":320,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/insys-therapeutics-inc-nasdaqinsy-returns-to-profitability-with-q4-earnings-16651#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Insys-Therapeutics-Inc..jpg","keywords":["Insys Therapeutics Inc. (NASDAQ:INSY)","NASDAQ:INSY"],"articleSection":["Business","Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/insys-therapeutics-inc-nasdaqinsy-returns-to-profitability-with-q4-earnings-16651#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/insys-therapeutics-inc-nasdaqinsy-returns-to-profitability-with-q4-earnings-16651","url":"https:\/\/cablemanpro.com\/wallstreetpr\/insys-therapeutics-inc-nasdaqinsy-returns-to-profitability-with-q4-earnings-16651","name":"Insys Therapeutics Inc. (NASDAQ:INSY) Returns to Profitability with Q4 Earnings - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/insys-therapeutics-inc-nasdaqinsy-returns-to-profitability-with-q4-earnings-16651#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/insys-therapeutics-inc-nasdaqinsy-returns-to-profitability-with-q4-earnings-16651#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Insys-Therapeutics-Inc..jpg","datePublished":"2014-03-06T14:15:46+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/insys-therapeutics-inc-nasdaqinsy-returns-to-profitability-with-q4-earnings-16651#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/insys-therapeutics-inc-nasdaqinsy-returns-to-profitability-with-q4-earnings-16651"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/insys-therapeutics-inc-nasdaqinsy-returns-to-profitability-with-q4-earnings-16651#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Insys-Therapeutics-Inc..jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/03\/Insys-Therapeutics-Inc..jpg","width":355,"height":142},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/insys-therapeutics-inc-nasdaqinsy-returns-to-profitability-with-q4-earnings-16651#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Insys Therapeutics Inc. (NASDAQ:INSY) Returns to Profitability with Q4 Earnings"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/60ece280249b1fa366ae54f87bb8ae84","name":"Donna Fago","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/06\/f15db860f556e28a86f628554c98485b.jpeg","caption":"Donna Fago"},"description":"I believe in writing content Informing investors with the knowledge they need to invest better today- I have been following the markets for many years and was asked to join the team at WallStreetPR.com recently due to my passion for the markets.","sameAs":["http:\/\/www.WallStreetPR.com"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/darcie-fago"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/16651","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=16651"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/16651\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/16669"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=16651"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=16651"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=16651"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=16651"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}